SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

NCT05163080 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

247

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed Glioblastoma

Interventions

BIOLOGICAL: SurVaxM

Sponsor

MimiVax, LLC

Collaborators

[object Object]
[object Object]